期刊文献+

苯甲酸阿格列汀合成研究进展

The Synthesis Research Progress of Alogliptin Benzoate
下载PDF
导出
摘要 介绍了苯甲酸阿格列汀的药学背景,从起始原料出发总结和归纳了苯甲酸阿格列汀的现有合成路线,并对每条路线进行了分析和总结。苯甲酸阿格列汀合成的主要起始原料有6-氯尿嘧啶、6-氯-3-甲基尿嘧啶、1-(2-异氰苄基)-3-甲基脲、丙二酸单乙酯和4-甲氧基-3-氧代丁腈。认为路线以6-氯-3-甲基尿嘧啶为起始原料,反应条件温和,后处理简单,更加符合工业化生产的要求。但应进一步优化反应条件,减少副反应发生,降低成本。 In this article,pharmaceutical background of alogliptin benzoate was generalized at first.Then current different synthetic processes of alogliptin benzoate were generalized and analyzed from starting raw material such as 6-chloro uracil,6-chloro-3-methyl uracil,1-(2-isocyano benzyl)-3-methyl urea,ethyl hydrogen malonate and 4-methoxy-3-oxobutanenitrile.The route with 6-chloro-3-methyl uracil as starting raw materials showed more favorable and commercial value in the manufacturing scale such as mild reaction conditions and simple post-processing,but the reaction conditions should be further optimized to reduce side effects and cost.
出处 《化工生产与技术》 CAS 2016年第2期36-40,8,共5页 Chemical Production and Technology
关键词 苯甲酸阿格列汀 合成路线 6-氯-3-甲基尿嘧啶 alogliptin benzoate synthesis rout 6-chloro-3-methyl uracil
  • 相关文献

参考文献22

  • 1Thomas G, Volker K, Ulrich J. Griesser. Alogliptin and its benzoate salt[J]. Acta Cryst, 2013,C69:674 - 678.
  • 2赵兴旺,吴冰,赵临襄.阿格列汀(Alogliptin)[J].中国药物化学杂志,2013,23(4):337-337. 被引量:7
  • 3Lucienne J J. Dipeptidyl peptidase IV and its inhibitors: Therapeutics for type 2 diabetes and what else?[J]. J Med Chem, 2014,57:2197-2212.
  • 4郝群,蔡正艳,周伟澄.二肽基肽酶-4抑制剂构效关系研究进展[J].世界临床药物,2009,30(8):487-497. 被引量:10
  • 5Thomas L, Eekhardt M, Langkopf E. (R)-8-(3-amino-pipefidin-1-yl) -7-but-2-ynyl-3-methyl- 1-(4-meth-ylquinazolin-2-ylmethyl)-3, 7- dihydro- purine- 2,6- dione(BI1356), a novel xanthine- based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase 4 inhibitor[J]. J Pharmacol Exp Ther, 2008,325(1): 175-182.
  • 6Bumsup L, Lihong S, Daniel B. Pharmacokinetic, pharmcodynamie,and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs and monkeys[J]. Eur J Pharmacol, 2008,589( 1/3):306-314.
  • 7Covington P, Christopher R, Daven- port M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, dou ble-blind, placebo-controlled, multiple- dose study in adult patients with type 2 diabetes[J]. Clin Ther, 2008,30(3):499-512.
  • 8治疗糖尿病的新药NESINA获批在日本上市[J].中国执业药师,2010(6):54-54. 被引量:12
  • 9Scott L J. Alogliptin: a review of its use in the management of type 2 diabetes mellitus[J]. Drugs, 2010,70(15):2051-2072.
  • 10Feng J. Dipeptidyl peptidase inhibitor: EP,1586571A[P]. 2005-10-19.

二级参考文献32

  • 1Feng J,Zhang Z,Wallace MB,et al.Discovery of alogliptin:A potent,selective,bioavailabe,and efficacious inhibitor of dipeptidyl peptidase IV[J].J Med Chem,2007,50(10):2297-2300.
  • 2Serradell N,Rose E,Bolos J.Alogliptin benzoate[J].Drug Future,2008,33(1):7-12.
  • 3Feng J,Gwaltney SL,Stafford JA,et al.Dipeptidyl peptidase inhibitors:WO,2007035629[P].2006,9,15.
  • 4FENG J,ZHANG Z,WALLACE M B,et al. Discovery of alo-gliptii\:a potent,selective,bioavailable,and efficacious inhibi-tor of dipeptidyl peptidase IV [ J] . J Med Chem,2007,50(10):2297-2300.
  • 5PRATLEY R E. Alogliptin ; a new,highly selective dipeptidylpeptidase-4 inhibitor for the treatment of type 2 diabetes[ J].Expert Opin Pharmacother,2009,10(3) :503 -512.
  • 6Takeda Pharmaceutical. Nesina ( alogliptin ) solution [ EB/OL]. [2013 -05 - 12]. http://www. accessdata. fda. gov/drugsatfda_docs/label/2013/02227ls0001bl.pdf.
  • 7DeFRONZO R A,BURANT C F,FLECK P,et al. Efficacyand tolerability of the DPP-4 inhibitor alogliptin combinedwith pioglitazone,in metformin-treated patients with type 2diabetes [ J]. J Clin Endocrinol Metab,2012,97(5): 1615 -1622.
  • 8Thoma R,Loeffler B,Stihle M,et al.Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV[J]. Stucture,2003; 11 (8):947-959.
  • 9Dipeptidyl peptidase inhibitor.Crystalline form of an organic compound[P]. US:2010072680,2010-07-01.
  • 10Mark Andres,Keith Lorimer.Polymorphs of benzoate salt of 2-[[6-[(30- 3-amino- 1 -p iperidinyl]-3,4-dihydro-3-methyl-2,4-di oxo- 1 (2h)- pyrimidinyl]methyl]-benzonitrile and methods of use therefor[P]. US:2007035372,2006-09-13.

共引文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部